Subscribe to the BioNews newsletter for free

Login
Advanced Search

Search for
BioNews

Like the Progress Educational Trust on Facebook


 


 

Immune cell gene therapy a success for one leukaemia patient

17 December 2012

By Joseph Jebelli

Appeared in BioNews 686

A seven-year-old girl with a highly aggressive form of leukaemia may have been 'cured' by an experimental therapy that harnesses the body's immune system to seek out and destroy the disease.

Emily Whitehead was recruited to a small scale clinical trial, involving 10 adults and two children at the Hospital of the University of Pennsylvania (HUP) and the Children's Hospital of Philadelphia (CHOP), USA after she relapsed twice following standard chemotherapy.

Emily's own T cells - specialised immune cells - were removed and genetically modified using an incapacitated version of the human immunodeficiency virus (HIV). Scientists used this virus to arm the T cells with a protein called chimeric antigen receptor (CAR). This molecule is capable of distinguishing cancer cells from the healthy ones by binding to another protein called CD19, which is found on the surface of cancer cells in leukaemia. Once reprogrammed in this way, Emily's T cells were injected back into her body, where they were able to detect and attack the cancer in the same way they would a foreign infection.

'Three weeks after receiving the treatment, she was in remission. Emily completely responded to her T cell therapy', said Dr Stephen Grupp, a paediatric oncologist at CHOP, whose team led the trial. 'We checked her bone marrow for the possibility of disease again at three months and six months out from her treatment, and she still has no disease whatsoever. The cancer-fighting T cells are still there in her body', he added.

Emily had acute lymphoblastic leukaemia (ALL) - the most common type of childhood cancer. While 85 percent of children with ALL recover after two years of standard chemotherapy, 15 percent remain resistant to such treatment. For this group, the only current option is to undergo bone marrow transplants, which carry a 20 percent mortality risk and often fails to rid the body of the disease. Professor Carl June, from the University of Pennsylvania's Abramson Cancer Centre, said: 'It is possible that in the future, this approach may reduce or replace the need for bone marrow transplantation'.

Nonetheless, the results are preliminary and three of the 12 patients in the trial did not respond to the therapy. Scientists are now calling for much larger clinical trials. The University of Pennsylvania, in partnership with Novartis, recently announced plans to build a Centre for Advanced Cellular Therapies (CACT) in Philadelphia to further explore the potential of T cell immunotherapy in the ongoing battle against cancer.

RELATED ARTICLES FROM THE BIONEWS ARCHIVE

22 February 2016 - by Julianna Photopoulos 
Trials using genetically engineered immune cells have shown 'extraordinary results' in treating blood cancers in terminally ill patients, say researchers...
14 December 2015 - by Dr James Heather 
Two patients enrolled in a clinical trial of a gene therapy to treat severe congenital immunodeficiency have shown signs of substantial improvement in their condition...
08 July 2013 - by Dr James Heather 
Two HIV patients that received bone marrow transplants have been able to stop taking their anti-viral drugs without any detectable reappearance of the virus, scientists have announced....
25 March 2013 - by John Brinsley 
Early results of an experimental gene therapy against an aggressive form of leukaemia have been hailed by researchers as showing 'life saving potential'....

05 November 2012 - by Dr Lucy Spain 
The European Medicines Agency (EMA) has approved Glybera, a gene therapy to treat a rare genetic condition, lipoprotein lipase deficiency (LPLD), for sale across Europe. Glybera is the first gene therapy to be approved for the Western market and offers the first therapeutic treatment for people with LPLD....
05 March 2012 - by Ayesha Jadoon 
Early trials in patients with chronic granulomatous disorder (x-CGD), a recessive X-linked condition that affects the immune system, have shown signs of success following the use of gene therapy. The observed boost in immunity of those undergoing treatment was only temporary, however, and the faulty gene causing x-CGD was not corrected permanently....
08 November 2009 - by Dr Rebecca Robey 
Gene therapy has been used to treat two young boys with a devastating and fatal brain disease called adrenoleukodystrophy (ALD). Two years after treatment, both boys showed signs that the disease had stopped progressing and that there were no serious side effects from the gene therapy. These results, published in the journal Science, show huge promise, both for the future treatment of ALD and for the revival of investigations into the use of gene therapy to treat a wide variety ...
01 September 2009 - by Lorna Stewart 
Research published earlier this month in Nature Genetics is the first to show that there is a genetic component to acute lymphoblastic leukaemia (ALL), the most common form of childhood cancer.
10 August 2009 - by Adam Fletcher 
The second complete cancer cell genome sequence was published online last week in the New England Journal of Medicine, representing a pioneering effort to comprehensively describe the hundreds of genetic changes that underlie this most insidious of diseases...

HAVE YOUR SAY
Comment (angusdobbie - Updated on 18/12/2012)
Thanks for another interesting and informative article.  My only comment is the use of the term HIV virus.  We are used to hearing this on the television and radio but am I alone in hoping the scietific literature remembers what the V in HIV stands for? In common use the term HIV is now taken for the disease rather than the virus so perhaps HIV virus is too established. But perhaps some would still disapprove, including the BBC Corporation, the EU Union and even the RSPCA Animals!

You need to or  to add comments.

By posting a comment you agree to abide by the BioNews terms and conditions


- click here to enquire about using this story.

Published by the Progress Educational Trust

CROSSING FRONTIERS

Public Conference
London
8 December 2017

Speakers include

Professor Azim Surani

Professor Magdalena Zernicka-Goetz

Professor Robin Lovell-Badge

Sally Cheshire

Professor Guido Pennings

Katherine Littler

Professor Allan Pacey

Dr Sue Avery

Professor Richard Anderson

Dr Elizabeth Garner

Dr Andy Greenfield

Dr Anna Smajdor

Dr Henry Malter

Vivienne Parry

Dr Helen O'Neill

Dr César Palacios-González

Philippa Taylor

Fiona Fox

Sarah Norcross

Sandy Starr


BOOK HERE

Good Fundraising Code

Become a Friend of PET HERE and give the Progress Educational Trust a regular donation